Oh my. Now another American desiccated thyroid (NDT) brand recall? Earlier this year, Acella's NP thyroid was found to be superpotent (over 110% on the T3 content), and they issued a voluntary recall. Now, as of August 25, 2020, Nature-Throid and/or WP-Thyroid are sub-potent, so their manufacturer RLC Labs is issuing a voluntary recall. QUOTE: … Continue reading RLC Labs issues Nature-Throid and WP-thyroid recall for subpotency
Acella, the makers of NP Thyroid, issued a voluntary recall notice on May 22, 2020. This is part 2 of a two-part series reviewing the drug recall notice's statements and the science behind them. [Part 1: Acella NP Thyroid recall: Ethical yet low-risk] We should applaud Acella for being so conscientious about the exact amounts … Continue reading Acella NP Thyroid recall: maternal risk inflated
Acella, the makers of NP Thyroid, issued a voluntary recall notice on May 22, 2020. This is part 1 of a two-part series reviewing the drug recall notice's statements and the science behind them. In this post, I put this recall in the context of pharmaceutical guidelines and manufacturing challenges. I also portray the variable … Continue reading Acella NP Thyroid recall: Ethical yet low-risk
In this review, I outline the strengths and weaknesses of Hoang et al's clinical trial of levothyroxine (LT4) and desiccated thyroid extract (here called DTE, also known as NDT, natural desiccated thyroid).
A clinical trial comparing Armour Thyroid (NDT) and Levothyroxine (LT4) is now recruiting patients in the United States. The sponsor of the study is Allergan, the makers of Armour Thyroid in the United States. They hope to recruit 220 patients at multiple locations listed on the clinical trial website. In this post, I provide what … Continue reading New clinical trial of Armour Thyroid is recruiting U.S. patients